Companies

Moderna in talks with many countries for supply of Covid-19 vaccine

Prashasti Awasthi Mumbai | Updated on August 06, 2020 Published on August 06, 2020

Moderna, an American biotechnology company, is in talks with numerous countries for supply deals for its much-awaited Covid-19 vaccine, the company said in an official statement.

The firm, which discovers and develops vaccines for various infections and diseases, said it would charge between $32 to $37 per dose, which it sees as cheaper “pandemic pricing”.

The company said it has already received $400 million in deposits from multiple governments for its potential vaccine against the virus.

Moderna’s vaccine candidate named mRNA-1273 will hit the markets as early as October, after finishing phase three of trials that have enrolled 30,000 people.

Moderna CEO Stephane Bancel said in the statement: “As we pivot to a commercial-stage company, we recognise the need for responsible pricing in the face of the pandemic.”

The company has received $1 billion from the US government in order to accelerate the development of the vaccine.

Moderna’s vaccine has RNA, which is a genetic material that causes cells to produce spike protein for coronavirus and induces an immune response from the body.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on August 06, 2020
This article is closed for comments.
Please Email the Editor